International gathering of more than 1,400 vascular specialists will feature the latest data on limb-threatening diseases, novel technology and integration of specialty within larger healthcare system
Rosemont, Ill. – April 24, 2026 – The American College of Surgeons (ACS) and Society for Vascular Surgery (SVS) have verified three hospitals through the Vascular Verification Program (Vascular-VP).
In November 2025, the New England Journal of Medicine published data from the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Study (CREST-2) trial.
Updated guidance incorporates new research to address non-operative management of BTAI, timing of repair and the management of patients with concomitant traumatic injuries.
William H. Baker, M.D., a past president of the American Association for Vascular Surgery (AAVS) and a longtime contributor to the Society for Vascular Surgery (SVS), died Dec. 1.
Froedtert & MCW Froedtert Hospital receives national verification from the American College of Surgeons Vascular Verification Program
Memorial Regional Hospital receives national verification from the American College of Surgeons Vascular Verification Program
Timely update comes as September marks Peripheral Artery Disease (PAD) Awareness Month
Rosemont, Ill. – July 17, 2025 — The Society for Vascular Surgery (SVS) acknowledges the increased public attention surrounding chronic venous insufficiency (CVI) following news reports of President Donald J.
Following extended negotiations in both the House and Senate, Congress narrowly passed a major reconciliation package, titled the One Big, Beautiful Bill Act (OBBBA), on July 3, which was signed into law by President Trump on July 4.
Rosemont, Ill. – The Society for Vascular Surgery (SVS) is pleased to announce the results of the 2025 elections for Vice President and Secretary, revealed today during the SVS Annual Business Meeting held as part of the Vascular Annual Meeting (VAM) in New Orleans, La.
Findings from a phase three, randomized controlled clinical trial demonstrate the superiority of Humacyte’s Acellular Tissue Engineered Vessel (ATEV) over autologous arteriovenous fistula (AVF) in high-risk patients with end-stage kidney disease (ESKD).
A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of cardiovascular events, major limb events, and inpatient admissions.
Findings from a comprehensive 20-year clinical study demonstrate treatment of functional popliteal artery entrapment syndrome (FPAES), particularly in combination with fasciotomy for exertional compartment syndrome, has shown highly effective outcomes, with 82% of patients returning to prior level of athletics.
Nearly 1,000 SVS members responded to an opinion poll (fielded in March/April) asking them to analyze key factors and assess whether a Federated Model for the Vascular Surgery Board (VSB) within the current American Board of Surgery (ABS) or a free-standing VSB outside of ABS, would best strength
Jim Craig, a longtime supporter and vascular advocate, will deliver the annual keynote address for the 2025 Vascular Annual Meeting (VAM25), held in New Orleans, June 4-7 at the Morial Convention Center.
According to a new national survey released by the Society for Vascular Surgery (SVS), primary care providers rank vascular disease among the top three health crises facing our aging population, only behind heart disease and cancer and ahead of obesity and diabetes.
The Vascular Surgery MVP Feedback from the CMS public comment period has been posted to the CMS website. The SVS is very grateful for all the feedback that was given. After reviewing the MVP candidates, the feedback for the Vascular Surgery MVP was consistent with other MVP candidates and issues previously identified by CMS.
The SVS is excited to announce that the Vascular Surgery MIPS Value Pathway (MVP) has been posted for public comment with CMS.
The Society for Vascular Surgery (SVS) and the Society for Vascular Nursing (SVN) join healthcare organizations nationwide in celebrating National Nurse Practitioner Week (Nov.
International gathering of more than 1,400 vascular specialists will feature the latest data on limb-threatening diseases, novel technology and integration of specialty within larger healthcare system
Rosemont, Ill. – April 24, 2026 – The American College of Surgeons (ACS) and Society for Vascular Surgery (SVS) have verified three hospitals through the Vascular Verification Program (Vascular-VP).
In November 2025, the New England Journal of Medicine published data from the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Study (CREST-2) trial.
Updated guidance incorporates new research to address non-operative management of BTAI, timing of repair and the management of patients with concomitant traumatic injuries.
William H. Baker, M.D., a past president of the American Association for Vascular Surgery (AAVS) and a longtime contributor to the Society for Vascular Surgery (SVS), died Dec. 1.
Froedtert & MCW Froedtert Hospital receives national verification from the American College of Surgeons Vascular Verification Program
Memorial Regional Hospital receives national verification from the American College of Surgeons Vascular Verification Program
Timely update comes as September marks Peripheral Artery Disease (PAD) Awareness Month
Rosemont, Ill. – July 17, 2025 — The Society for Vascular Surgery (SVS) acknowledges the increased public attention surrounding chronic venous insufficiency (CVI) following news reports of President Donald J.
Following extended negotiations in both the House and Senate, Congress narrowly passed a major reconciliation package, titled the One Big, Beautiful Bill Act (OBBBA), on July 3, which was signed into law by President Trump on July 4.
Rosemont, Ill. – The Society for Vascular Surgery (SVS) is pleased to announce the results of the 2025 elections for Vice President and Secretary, revealed today during the SVS Annual Business Meeting held as part of the Vascular Annual Meeting (VAM) in New Orleans, La.
Findings from a phase three, randomized controlled clinical trial demonstrate the superiority of Humacyte’s Acellular Tissue Engineered Vessel (ATEV) over autologous arteriovenous fistula (AVF) in high-risk patients with end-stage kidney disease (ESKD).
A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of cardiovascular events, major limb events, and inpatient admissions.
International gathering of more than 1,400 vascular specialists will feature the latest data on limb-threatening diseases, novel technology and integration of specialty within larger healthcare system
Rosemont, Ill. – April 24, 2026 – The American College of Surgeons (ACS) and Society for Vascular Surgery (SVS) have verified three hospitals through the Vascular Verification Program (Vascular-VP).
In November 2025, the New England Journal of Medicine published data from the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Study (CREST-2) trial.
Updated guidance incorporates new research to address non-operative management of BTAI, timing of repair and the management of patients with concomitant traumatic injuries.
William H. Baker, M.D., a past president of the American Association for Vascular Surgery (AAVS) and a longtime contributor to the Society for Vascular Surgery (SVS), died Dec. 1.
Froedtert & MCW Froedtert Hospital receives national verification from the American College of Surgeons Vascular Verification Program
Memorial Regional Hospital receives national verification from the American College of Surgeons Vascular Verification Program
Timely update comes as September marks Peripheral Artery Disease (PAD) Awareness Month
Rosemont, Ill. – July 17, 2025 — The Society for Vascular Surgery (SVS) acknowledges the increased public attention surrounding chronic venous insufficiency (CVI) following news reports of President Donald J.
Following extended negotiations in both the House and Senate, Congress narrowly passed a major reconciliation package, titled the One Big, Beautiful Bill Act (OBBBA), on July 3, which was signed into law by President Trump on July 4.
Rosemont, Ill. – The Society for Vascular Surgery (SVS) is pleased to announce the results of the 2025 elections for Vice President and Secretary, revealed today during the SVS Annual Business Meeting held as part of the Vascular Annual Meeting (VAM) in New Orleans, La.
Findings from a phase three, randomized controlled clinical trial demonstrate the superiority of Humacyte’s Acellular Tissue Engineered Vessel (ATEV) over autologous arteriovenous fistula (AVF) in high-risk patients with end-stage kidney disease (ESKD).
A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of cardiovascular events, major limb events, and inpatient admissions.